CEConversations

This podcast focuses on educating, informing, and empowering clinicians involved in the care of patients with triple-negative breast cancer (TNBC) to positively impact the racial/ethnic disparities that negatively impact Black women. Our faculty will explore strategies that promote equitable care and outcomes for all patients; evaluate the role of antibody-drug conjugates (ADCs) in TNBC; and discuss the rapidly evolving clinical practice guidelines, safety and efficacy data of novel therapies, and practical ADC management strategies to anticipate and mitigate adverse events. To claim credit, visit: https://www.ceconcepts.com/activity/actionable-strategies-in-community-oncology-to-achieve-equity-in-triple-negative-breast-cancer-3/

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/iv-iron-expert-exchange-podcast
In this Expert Exchange-based format, activity attendees will be immersed in a lively discussion between key thought leaders in the world of HF. Expert discussion will include an exploration of clinical trial data for intravenous (IV) iron therapies in HF and recently-updated expert consensus HF management guidelines, with emphasis on the emerging role of IV iron on improved clinical endpoints in HFrEF. Key teaching points up for debate include the safety and efficacy profiles of next-generation IV iron products, established and emerging clinical trial data in HF, and a comparative analysis of currently-available IV iron products.

To receive up to 1.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/navigating-ckd-podcast#group-tabs-node-course-default1
To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events. Erythropoietin-stimulating agents (ESAs) are associated with significant cardiovascular safety-related concerns, but the emergence of the oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) may improve erythropoiesis without the undesirable downstream effects of ESAs. However, HIF-PHIs place in therapy has not yet been fully elucidated. Here, join the interprofessional team of Dr. Ajay Singh, Dr. Jane Davis, and Dr. Calvin Meaney as they explore an incisive review of current CKD-anemia treatment and diagnostic challenges, as well as the evidentiary base for HIF-PHI utilization in CKD-anemia that establishes context for the future of these agents. In conclusion, a practical discussion of real-world patient case scenarios will be presented, to provide learners with context of the multiple comorbidities, complexities, diagnostic challenges, and barriers to appropriate treatment of CKD-anemia.

To receive up to 2.0 CME/CE credit please complete the evaluation and request form here: https://www.ceconcepts.com/2022chest-podcast
This dynamic live symposium, led by top experts in the field of pulmonary medicine and NSCLC, will take attendees on a deep dive into the sentinel role of the pulmonologist in the NSCLC management paradigm, exploring adaptive mechanisms to optimize collaborative strategies in a patient centric manner.
Learning Objectives

• Review the sentinel placement of the pulmonologist in the management of NSCLC, including their principal role in diagnostics, disease staging, and molecular testing.
• Evaluate clinical and patient-value driven factors that may help inform nodule evaluation and diagnostic strategies for pulmonologists, thus ensuring “the right tissue in the right amount from the right place for the right patient.”
• Demonstrate knowledge of guideline recommendations and practical considerations for the use of EBUS-TNBA techniques by pulmonologists, emphasizing the fundamentals of safely and effectively obtaining adequate tissue for diagnosis and molecular characterization.
• Describe the evolving role of targeted therapy and immunotherapy in NSCLC and analyze currently FDA-approved therapeutics across the NSCLC disease continuum, highlighting the role of molecular testing for guiding treatment and individualizing patient care.
• Explore the established utility of next-generation sequencing (NGS) and discuss the potential for emerging “next-generation” biomarkers in the NSCLC management paradigm.
• Apply patient-centric, evidence-supported collaborative care strategies to real-world, case-based scenarios in order to elucidate the pivotal role of the pulmonologist on the multidisciplinary team across the NSCLC continuum of care.

Presented by Creative Educational Concepts, LLC.

Supported through an independent educational grant from AstraZeneca.

Learning Objectives

• Review the formative facets of iron absorption and metabolism, including the practical distinctions between functional and absolute iron deficiency, with expert analysis of how these principles dictate treatment approaches.
• Summarize the multifactorial etiologies and complex pathophysiology of cancer-related anemia (CRA) and chemotherapy-induced anemia (CIA), emphasizing the implications of CRA/CIA on oncologic outcomes and patient-centric metrics.
• Appraise completed, ongoing, and planned clinical trials of IV iron products in CRA/CIA, highlighting the established ability of these agents to enhance hematopoietic response rates, decrease transfusion burden, and improve patient outcomes.
• Discuss how next-generation IV iron products have dramatically improved upon the safety profiles of earlier generation agents, particularly with respect to severe hypersensitivity reactions.
• Review current expert consensus guidelines for CRA/CIA management from ASCO/ASH, NCCN, and ESMO.
• Use real-world patient cases to evaluate evidence-supported strategies that members of the multidisciplinary and interprofessional cancer care team can use to safely and effectively implement IV iron into clinical practice.
• Compare and contrast the unique clinical utility of currently-approved IV iron agents, emphasizing the impact of differential safety profiles on treatment decisions.
• Investigate the clinical implications of IV iron-associated hypophosphatemia in all patients, but especially in those with cancer and/or those actively receiving chemotherapy.

Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from Pharmacosmos Therapeutics, Inc.